Tenaya Therapeutics (TNYA) Share-based Compensation (2020 - 2026)

Tenaya Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• On a quarterly basis, Share-based Compensation fell 41.14% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was -$436000.0, a 102.72% decrease from a year earlier, with the FY2025 full-year figure at $7.8 million, down 52.73% from the prior year.
• Share-based Compensation climbed to $2.2 million in Q1 2026 per TNYA's latest filing, from -$9.2 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $4.6 million in Q2 2024 and bottomed at -$9.2 million in Q4 2025.
• The 5-year median for Share-based Compensation is $3.6 million (2025), against an average of $2.7 million.
• Across the five-year window, Share-based Compensation surged 500.0% in 2022 and sank 344.77% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $3.2 million in 2022, then gained by 23.91% to $3.9 million in 2023, then decreased by 4.81% to $3.8 million in 2024, then slumped by 344.77% to -$9.2 million in 2025, then surged by 123.87% to $2.2 million in 2026.
• Per Business Quant, the three latest TNYA Share-based Compensation figures stand at $2.2 million (Q1 2026), -$9.2 million (Q4 2025), and $2.9 million (Q3 2025).